Clinical trials: Type 2 Diabetes (T2D)
Diabetes Mellitus, Type 2
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D).
- Trial name
- NCT05478252
- Testing
- Semaglutide J, Semaglutide B
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
- Trial name
- NCT01514149
- Testing
- CJC-1134-PC Injection
- Where
- 22 sites in United States, Canada
- Volunteers
- 73 people
- Sponsor
- ConjuChem
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of treatment with CCX140-B in subjects with diabetic nephropathy.
- Trial name
- NCT01447147
- Testing
- CCX140-B
- Where
- 83 sites in Belgium, Czechia and 4 more
- Volunteers
- 332 people
- Sponsor
- Amgen
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an…
- Trial name
- NCT04606576
- Testing
- ORMD-0801 QD, ORMD-0801 BD
- Where
- United States
- Volunteers
- 710 people
- Sponsor
- Oramed, Ltd.
Diabete Mellitus
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2…
- Trial name
- NCT07239440
- Testing
- DA-2811, DA-2811-C
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Dong-A ST Co., Ltd.
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT01081834
- Testing
- Canagliflozin, Sitagliptin
- Where
- 78 sites in United States, Austria and 16 more
- Volunteers
- 678 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK).
- Trial name
- NCT03960814
- Testing
- Insulin detemir
- Where
- Denmark
- Volunteers
- 12,847 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
- Trial name
- NCT01001104
- Testing
- LY2189265
- Where
- 6 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Type 2
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3…
- Conditions
- Diabetes, Diabetes Type 2, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- REGENT-1-US (NCT05014204)
- Testing
- The Endogenex Device
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endogenex, Inc.
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
20 eligible subjects will be enrolled into the treatment phase of the trial.
- Trial name
- NCT00642538
- Testing
- MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient…
- Trial name
- NCT05318326
- Testing
- Yogliptin 400mg group, Yogliptin 200mg group
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
Diabetes, Diabetes Mellitus, Type 1
Paediatric Subjects - Special Survey
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538576
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects
This trial is conducted in Europe. The aim of this first human dose trial is to investigate the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (exposure of the trial…
- Trial name
- NCT01809184
- Testing
- insulin 287, insulin glargine
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Chiglitazar Added to Metformin for Type 2 Diabetes
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.
- Trial name
- NCT04807348
- Testing
- Chiglitazar 32mg, Chiglitazar 48mg, Metformin Hydrochloride
- Where
- 50 sites in China
- Volunteers
- 533 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
The study will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide among participants with…
- Trial name
- ENI-SPIRE-2 (NCT07889648)
- Testing
- Enicepatide, Tirzepatide
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan
This study is intended to prospectively research the treatment reality and long-term disease control of Type 2 Diabetes Mellitus (T2DM) patients who are initiating 2nd line anti-diabetes treatment in sites across Japan.
- Trial name
- J-DISCOVER (NCT02226822)
- Where
- 106 sites in Japan
- Volunteers
- 1,869 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.